At a glance
ClinicalIndex Comparison RecordN/ACompleted· 459 enrolled
Drug / intervention
Coaptite®device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-approval of Coaptite® in the Treatment of Female Urinary Incontinence
In Brief
A clinical study evaluating Coaptite® for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency. Completed, enrolled 459 participants across 20 sites.
Detailed Summary
This is a post approval study of Coaptite® in the treatment of female urinary incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedOct 2009
Primary CompletionOct 2015
Study CompletionNov 2015
TodayJul 2026
First PostedOct 16, 2009
Enrollment StartJan 8, 2008
Primary CompletionOct 26, 2015
Study CompletionNov 2, 2015
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 16.7 years ago
Interventions
Coaptite®device
Calcium hydroxylapatite particles suspended in an aqueous based gel carrier